Prospective randomized study of prophylaxis of superficial bladder cancer with epirubicin: the role of a central pathology laboratory

1994 ◽  
Vol 35 (S1) ◽  
pp. S36-S40 ◽  
Author(s):  
Yoshihiko Hirao ◽  
Seiichiro Ozono ◽  
Hitoshi Momose ◽  
Eigoro Okajima ◽  
Tadashi Hiramatsu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Randomized Study ◽  
Prospective Randomized Study ◽  
Pathology Laboratory ◽  
Central Pathology

scholarly journals Intravesical Electromotive Mitomycin C Versus Passive Transport Mitomycin C for High Risk Superficial Bladder Cancer: A Prospective Randomized Study

2003 ◽  
Vol 170 (3) ◽  
pp. 777-782 ◽  
Author(s):  
SAVINO M. DI STASI ◽  
ANTONELLA GIANNANTONI ◽  
ROBERT L. STEPHEN ◽  
GIOVANNI CAPELLI ◽  
PIERLUIGI NAVARRA ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Randomized Study ◽  
Prospective Randomized Study ◽  
Passive Transport

Neoadjuvant Chemotherapy Plus Cystectomy Compared With Cystectomy Alone for Locally Advanced Bladder Cancer

2021 ◽  
pp. 141-146
Author(s):  
Vikram M. Narayan
Keyword(s):  
Adverse Effect ◽  
Overall Survival ◽  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Randomized Study ◽  
Locally Advanced ◽  
Common Adverse Effect ◽  
Advanced Bladder Cancer ◽  
Muscle Invasive

This study summarizes a landmark study on the role of neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in patients with muscle-invasive bladder cancer. This randomized study of M-VAC plus cystectomy versus cystectomy alone suggested improved overall survival in patients receiving neoadjuvant therapy. Severe granulocytopenia was a common adverse effect in the chemotherapy group, but no deaths were attributed to chemotherapy.

Superficial Bladder Cancer Therapy: A Review

2005 ◽  
Vol 72 (3) ◽  
pp. 307-317
Author(s):  
P.F. Bassi ◽  
V. Serretta ◽  
F. Pinto ◽  
A. Calpista ◽  
A. Galuffo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transurethral Resection ◽  
Superficial Bladder Cancer ◽  
Risk Groups ◽  
Tumor Stage ◽  
Intravesical Therapy ◽  
Size Number ◽  
Muscle Invasion ◽  
Prevention Of Recurrence

Most bladder cancers present as a superficial disease, confined to the bladder mucosa or submucosal layer, without muscle invasion. Most superficial tumors have a propensity for recurrence after transurethral resection; some have a high risk for progression to muscle invasion. The treatment aim in superficial bladder cancer with intravesical therapy is three-fold: (1) eradicate existing disease, (2) prevention of recurrence, (3) prevention of tumor progression. The prognostic factors (tumor stage, grade, size, number and recurrence pattern) allow the stratification of tumors in different risk groups to plan treatment. Studies on pharmacokinetics have proved the efficacy of optimized drug delivery. Comparing resection with and without intravesical chemotherapy, a short-term reduction, approximately 15%, in tumor recurrence with chemotherapy can be obtained, but no effect on progression was proven. No agent has proved to be more effective than the others. A single instillation of chemotherapy immediately after transurethral resection has proven to be effective, but the role of maintenance therapy is controversial. Immunotherapy, in the form of Bacillus Calmette-Guerin, is generally shown to be more effective than chemotherapy, even if the results in comparison to mitomycin C do not result conclusive. Several new approaches are being explored to improve the efficacy of this therapy.

Sign in / Sign up

Export Citation Format

Share Document